Wirkstoffe & Arzneimittelsicherheit

Gegenanzeigen · Drovelis

Drovelis 3 mg/14.2 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5–6

HOS-146440 · Präparat HOS-099526

5  - ATE - current ATE, history of ATE (e.g. myocardial infarction [MI]) or prodromal condition (e.g. angina pectoris). - Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack [TIA]). - Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant). - History of migraine with focal neurological symptoms. - A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as: - diabetes mellitus with vascular symptoms; - severe hypertension; - severe dyslipoproteinaemia. - Presence or history of severe hepatic disease as long as liver function values have not returned to normal. - Severe renal insufficiency or acute renal failure. - Presence or history of liver tumours (benign or malignant). - Known or suspected sex steroid-influenced malignancies (e.g. of the genital organs or the breasts). - Undiagnosed vaginal bleeding.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.